Chemotherapy with a molecular rational basis, pentoxifylline as a promising antitumor drug.

In another way PTX therapy (0.6 mg/day) for 2 weeks in mice engrafted with L-1 sarcoma cells induced a highly significant reduction in tumor size, and this PTX therapy exhibited synergy with sulindac (0.5 mg/p.o./day), a nonsteroidal anti-inflammatory.

also in 132,142 other papers